Recalcitrant Lichen Planopilaris and Frontal Fibrosing Alopecia Responding to Tildrakizumab

    May 2020 in “ Dermatologic therapy
    Lara Trindade de Carvalho, Nekma Meah, Dmitri Wall, Rodney Sinclair
    Studysummary In this study, a patient with recalcitrant lichen planopilaris and frontal fibrosing alopecia showed significant improvement after receiving four doses of the interleukin-23 monoclonal antibody tildrakizumab. Our plain-language summary of this paper — not a Tressless recommendation.
    The paper reported a case of recalcitrant lichen planopilaris (LPP) and frontal fibrosing alopecia (FFA) that showed significant clinical improvement after four doses of tildrakizumab, an interleukin-23 monoclonal antibody. LPP and FFA are types of lymphocytic, cicatricial alopecias, with LPP presenting as multifocal patchy alopecia and FFA causing hairline recession. The treatment aimed to arrest the inflammatory process, which is often challenging and yields variable responses.
    Discuss this study in the Community →

    Research cited in this study

    8 / 8 results